IL-7

OSE Immunotherapeutics Receives U.S. Patent Notice of Allowance for Tedopi®

Retrieved on: 
Tuesday, September 7, 2021

NANTES, France, Sept. 07, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) announced today that it has received notice of allowance from the United States Patent and Trademark Office for a patent application related to Tedopi®, a combination of neoepitopes, protecting its administration schedule for inducing early T-lymphocyte memory response, used in the treatment of non-small cell lung cancer (NSCLC) in HLA-A2 positive patients. This patent will provide a protection until 2035.

Key Points: 
  • Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics, said: This new patent notice of allowance granted in the U.S. further expands the patent protection for Tedopi and confirms a specific mechanism of action inducing an early T-lymphocyte memory response in HLA-A2 positive patients, which represent 45% of the population.
  • Such combinations will further reinforce the therapeutic value of Tedopi in late stage cancer indications.
  • The Tedopi treatment is compared to docetaxel or pemetrexed chemotherapy (CT) treatments, with overall survival as the primary endpoint.
  • OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.

OSE Immunotherapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Retrieved on: 
Wednesday, September 1, 2021
Company, IL-7, Inflammation, Fortification, Cancer, Severe acute respiratory syndrome coronavirus 2, Large-cell lung carcinoma, GLOBE, Immune system, Boehringer Ingelheim, Ulcerative colitis, Research, Macrophage, Tissue, OSE, Immunotherapy, Epitope, Degenerative disease, B cell, ISIN, Partnership, CEO, Veloxis Pharmaceuticals, Autoimmune disease, Conference, Vaccination, Pancreatic cancer, COVID-19, Nivolumab, Animal, Vaccine, Pharmaceutical industry

NANTES, France, Sept. 01, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173) today announced it will present at the H.C. Wainwright 23rd Annual Global Investment Conference.

Key Points: 
  • NANTES, France, Sept. 01, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173) today announced it will present at the H.C. Wainwright 23rd Annual Global Investment Conference.
  • If you are an institutional investor and would like to attend the Companys presentation, please click on the following link to register for the conference: www.hcwevents.com .
  • Once your registration is confirmed, you will be prompted to log into the conference website to request a one-on-one meeting with the Company.
  • OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome

Retrieved on: 
Wednesday, August 25, 2021
IL-7, CD127, Research and development, Growth, Group, IL7, Social media, Human, Incidence, GLOBE, Lists of diseases, Drug, Ulcerative colitis, Cardiology, EUR, OSE, D, Heart, Foundation, Degenerative disease, Safety, ISIN, Partnership, Patient, Xerostomia, CEO, Autoimmune disease, Meta-analysis, Exercise, Neuroscience, Social, Pharmaceutical industry, Vaccine

PARIS and NANTES, France, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group, and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnmo: OSE), a French biotech, have announced enrollment of the first patient in the Phase 2 clinical trial of OSE-127/S95011 in Sjgrens syndrome, with Servier sponsorship.

Key Points: 
  • PARIS and NANTES, France, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group, and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnmo: OSE), a French biotech, have announced enrollment of the first patient in the Phase 2 clinical trial of OSE-127/S95011 in Sjgrens syndrome, with Servier sponsorship.
  • This international, randomized, double-blind, placebo-controlled Phase 2 study aims to evaluate the efficacy and safety of OSE-127/S95011 in patients with Sjgren's syndrome.
  • Sjgren's syndrome is an autoimmune disease characterized by lymphoid infiltration of the salivary and lacrimal glands leading to dry mouth and eyes.
  • An initial Phase 2 study under the sponsorship of OSE Immunotherapeutics is currently underway in ulcerative colitis.

NeoImmuneTech Appoints Jean Fan, M.D., as Chief Clinical Officer

Retrieved on: 
Wednesday, August 25, 2021
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Industry, IL-7, Company, CCO, GIST, Infection, Medical college, Blueprint, Cancer, Eisai, Sun, Master of Science, Leadership, Drug, Boehringer Ingelheim, PricewaterhouseCoopers, NIT, KOSDAQ, Assistant, Georgetown University School of Medicine, Bristol Myers Squibb, BMS, Clinical trial, International Association for Dance Medicine & Science, Patient, GlaxoSmithKline, Immunity, Medical College of Nanchang University, Novartis, Amgen, Jean Fan, VP, Hematology, FDA, GSK, Nanchang University, Eli Lilly, AstraZeneca, Pharmaceutical industry, NT-I7, NeoImmuneTech, NT-I7, NEOIMMUNETECH

NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced the appointment of Jean Fan, M.D., as Chief Clinical Officer (CCO).

Key Points: 
  • NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced the appointment of Jean Fan, M.D., as Chief Clinical Officer (CCO).
  • Fan brings over 20 years of experience in oncology and hematology leadership and clinical development to this role.
  • Fans contributions to our Clinical Development team thus far, and I am pleased to welcome her to the newly created role of Chief Clinical Officer, said Se Hwan Yang, Ph.D., President and Chief Executive Officer of NeoImmuneTech (NIT).
  • Fan joined NIT in 2020 as VP, Head of Clinical Development, coming from Blueprint Medicines where she served as VP, Clinical Development.

OSE Immunotherapeutics Announces Upcoming Investor Conferences and R&D Day

Retrieved on: 
Tuesday, August 24, 2021
Company, IL-7, Inflammation, Fortification, Cancer, Severe acute respiratory syndrome coronavirus 2, Large-cell lung carcinoma, GLOBE, Immune system, Boehringer Ingelheim, Ulcerative colitis, Research, Macrophage, Tissue, OSE, Immunotherapy, Epitope, Degenerative disease, B cell, ISIN, Partnership, Veloxis Pharmaceuticals, Autoimmune disease, Conference, Vaccination, Pancreatic cancer, COVID-19, Nivolumab, Mobile phone, Animal, Vaccine, Pharmaceutical industry

OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.

Key Points: 
  • OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.
  • The companys immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation.
  • In Phase 2 in non-small cell lung cancer in combination with nivolumab, sponsor Italian foundation FoRT.
  • OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

Q32 Bio Announces Appointment of Kathy LaPorte to its Board of Directors

Retrieved on: 
Tuesday, August 3, 2021

CAMBRIDGE,Mass., Aug. 3, 2021 /PRNewswire/ -- Q32 Bio , a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Kathy LaPorte to its Board of Directors.

Key Points: 
  • CAMBRIDGE,Mass., Aug. 3, 2021 /PRNewswire/ -- Q32 Bio , a clinical stage biotechnology company developing biologic therapeutics to restore immune homeostasis, today announced the appointment of Kathy LaPorte to its Board of Directors.
  • Ms. LaPorte, who brings over 30 years of experience in executive leadership and venture investing within the biotech industry, will serve as the Chair of the Audit Committee of the Board.
  • "It is a pleasure to welcome Kathy, a deeply experienced industry leader, to our Board of Directors," said Mike Broxson, Chief Executive Officer of Q32 Bio.
  • "I am delighted to join the Board at this exciting time in the Company's evolution," said Ms. LaPorte.